Yarrow Bioscience completes VYNE merger and begins Phase 2 trial of YB-101

Harbour BioMed and Sinopharm establish innovation R&D consortium

argenx agrees to acquire Forte Biosciences for USD2.2bn to add anti-CD122 antibody FB102

AstraZeneca reports positive Phase III survival results for Sone-Ve in advanced gastric cancers

Faron reports encouraging first overall survival data from BEXMAB frontline HR-MDS trial

NewAmsterdam Pharma and Menarini Group report positive CHMP opinion for obicetrapib monotherapy and obicetrapib/ezetimibe combination

CHMP backs Gilead's Trodelvy-Keytruda combination for first-line metastatic triple-negative breast cancer

Active Biotech doses first patient in amended tasquinimod myelofibrosis study

Ipsen's Phase III BOLD trial misses primary endpoint in biliary atresia

Sanofi ends atopic dermatitis development for amlitelimab

ArkBio completes Australian dosing in Phase I trial of influenza AFC drug AK0406

Lilac Biosciences and Soin Neuroscience publish clinical review on RNA biomarkers for neuropathic pain

Synaptiq Therapeutics launches and acquires clinical-stage SYN-001 programme

Bio-Thera Solutions reports first patient dosed in Phase 1 study of BAT8013

EU approves AstraZeneca's Etcamah combination for 1st-line ER-positive advanced breast cancer